Results 11 to 20 of about 15,116 (246)

Experience in using levodopa-benserazide [PDF]

Неврология, нейропсихиатрия, психосоматика, 2015
Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova   +3 more
doaj   +2 more sources

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Neuropsychiatric Disease and Treatment, 2008
David J BrooksDivision of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UKAbstract: After 40 years of clinical experience, levodopa remains the gold standard treatment for Parkinson’s disease (PD) despite ...
David J Brooks
doaj   +1 more source

Levodopa versus non-levodopa brain language fMRI in Parkinson’s disease [PDF]

Einstein (São Paulo), 2012
Objective: To identify the effect of levodopa in language areas inParkinson’s disease patients. Methods: We evaluated 50 patientswith mild to moderate Parkinson’s disease, age and gender pairedto 47 healthy volunteers.
Paula Ricci Arantes, Heloise Helena Gobato, Bárbara Bordegatto Davoglio, Maria Ângela Maramaldo Barreiros, André Carvalho Felício, Orlando Graziani Povoas Barsottini, Luiz Augusto Franco de Andrade, Edson Amaro Junior   +7 more
doaj   +1 more source

Levodopa-induced pseudopheochromocytoma [PDF]

European Journal of Case Reports in Internal Medicine, 2023
Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso, Ana Silveira, Sara Duarte, Ruth Fortes, Ahmed Botelho, Ana Simas, Rui Suzano   +6 more
openaire   +4 more sources

Sex differences in levodopa pharmacokinetics in early Parkinson’s disease: implications on levodopa-related complications

Frontiers in Pharmacology
IntroductionWomen with Parkinson’s Disease (PD) have higher plasma exposure to levodopa and are particularly prone to developing complications during chronic levodopa therapy. However, there are no longitudinal studies focusing on differences in levodopa
Valeria Conti, Valeria Conti, Emanuela De Bellis, Graziamaria Corbi, Bruno Charlier, Bruno Charlier, Viviana Izzo, Viviana Izzo, Maria Claudia Russillo, Marianna Amboni, Marianna Amboni, Marina Picillo, Marina Picillo, Cesa Lorella Maria Scaglione, Ilaria Cani, Calogero Edoardo Cicero, Alessandra Nicoletti, Andrea Soricelli, Paolo Barone, Paolo Barone, Amelia Filippelli, Amelia Filippelli, Maria Teresa Pellecchia, Maria Teresa Pellecchia   +23 more
doaj   +2 more sources

Effects of on Levodopa Pharmacokinetics

Journal of Parkinson’s Disease, 2021
Background: Infection with Helicobacter pylori seems overrepresented in Parkinson’s disease. Clinical observations suggest a suboptimal treatment effect of levodopa in Helicobacter positive patients. Objective: Describe and explain the connection between
Dag Nyholm, Per M. Hellström
doaj   +2 more sources

Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan

Frontiers in Pediatrics, 2021
Introduction: Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5–1 mg/kg/day).
Kyoko Hoshino, Kyoko Hoshino, Kyoko Hoshino, Masaharu Hayashi, Masaharu Hayashi, Masaharu Hayashi, Asayo Ishizaki, Asayo Ishizaki, Kazue Kimura, Kazue Kimura, Masaya Kubota, Masaya Kubota, Atsuo Nezu, Atsuo Nezu, Akihiro Yasuhara, Akihiro Yasuhara   +15 more
doaj   +1 more source

Levodopa exacerbated tremor in Parkinson's disease

Frontiers in Neurology
BackgroundLevodopa is considered the most effective pharmacological therapy for Parkinson's disease (PD). However, it can cause side effects including diverse types of dyskinesia.
José Fidel Baizabal-Carvallo, Marlene Alonso-Juarez, Robert Fekete   +2 more
doaj   +2 more sources

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Frontiers in Neurology, 2022
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations ...
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi   +7 more
doaj   +1 more source

Levodopa responsive gait dynamics in OFF- and ONOFF-state freezing of gait in Parkinson’s disease

Clinical Parkinsonism & Related Disorders, 2023
Background: In people with Parkinson’s disease (PwPD), Freezing of Gait (FOG) episodes can be levodopa responsive (OFF-FOG) or levodopa unresponsive (ONOFF-FOG).
Tuhin Virmani, Lakshmi Pillai, Aliyah Glover, Reid D. Landes   +3 more
doaj   +1 more source